AZ’s Ticagrelor, Boehringer’s Triple Combo Added to MHLW Panel’s Review Agenda for May 27

AstraZeneca’s oral antiplatelet agent ticagrelor and Nippon Boehringer Ingelheim’s triple combo hypertension drug will come up for approval review by a key advisory panel of the Ministry of Health, Labor and Welfare (MHLW) on May 27. MHLW officials told reporters...read more